Dacomitinib
| CAS No. | 1110813-31-4 |
|---|---|
| MDL No. | MFCD19443734 |
| MF | C24H25ClFN5O2 |
| MW | 469.90 |
| InChI Key | LVXJQMNHJWSHET-AATRIKPKSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Dacomitinib is a 7-methoxyquinazoline-4,6-diamine with the 4-amino group substituted by a 3-chloro-4-fluorophenyl group and the 6-amino group substituted by an (E)-4-(piperidin-1-yl)but-2-enoyl group. It functions as an epidermal growth factor receptor antagonist and antineoplastic agent. It belongs to the classes of quinazolines, piperidines, enamides, monochlorobenzenes, monofluorobenzenes, tertiary amino compounds, secondary amino compounds, and secondary carboxamides.
| CAS No. | 1110813-31-4 |
|---|---|
| Product Name | Dacomitinib |
Biological Targets
EGFR·ERBB2·ERBB4
Associated Conditions
upper aerodigestive tract neoplasm·brain cancer·colorectal cancer·metastasis·squamous cell carcinoma·
* The information provided here is compiled from public sources and is for reference only.
